Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
Agios Pharmaceuticals, Inc. (AGIO) Chief Medical Officer Sarah Gheuens exercised options covering 7,866 shares at an exercise price of $25.01 per share on October 26, 2026, acquiring common stock, then sold 7,866 shares at a weighted average price of $37.69 per share under a Rule 10b5-1 trading plan. Sale prices ranged from $37.53 to $38.06. After the exercise, she held options covering 16,275 shares, expiring March 1, 2033.
Agios Pharmaceuticals, Inc. officer Sarah Gheuens reported a planned sale of 7,866 common shares, with an approximate sale date of October 26, 2026, and an aggregate market value of $296,467.97. Morgan Stanley Smith Barney LLC is listed as broker, and NASDAQ as the exchange. The shares are listed as acquired from the issuer through a stock option exercise, with cash payment on October 26, 2026. Earlier sales listed for Gheuens were 500 shares on October 22, 2026 ($18,760.00), 1,489 shares on October 21, 2026 ($55,881.28), and 30,000 shares on August 4, 2026 ($914,283.00).
Agios Pharmaceuticals, Inc. Chief Medical Officer Sarah Gheuens exercised options to acquire 1,489 shares on October 21, 2026, and 500 shares on October 22, 2026, at an exercise price of $25.01 per share. She sold the same share amounts on those dates at $37.53 and $37.52 per share, respectively. Both sales were made under a Rule 10b5-1 trading plan; the October 21 sale price was a weighted average of sales ranging from $37.52 to $37.55.
Agios Pharmaceuticals, Inc. officer Sarah Gheuens reported a proposed sale of 500 common shares, with an aggregate market value of $18,760.00; October 22, 2026 is listed as the approximate sale date. The 500 shares are listed as acquired from the issuer through a stock option exercise for cash on October 22, 2026. Morgan Stanley Smith Barney LLC is listed as broker, and NASDAQ as the exchange.
Agios Pharmaceuticals officer Sarah Gheuens reported a proposed sale of 1,489 common shares, with October 21, 2026, listed as the approximate sale date. The proposed sale is listed through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate aggregate market value of $55,881.28. The shares were acquired through a stock option exercise from the issuer for cash.
AGIOS PHARMACEUTICALS, INC. Chief Medical Officer Sarah Gheuens reported selling 30,000 shares of common stock on August 4, 2026 at a weighted average price of $30.48 per share, with sale prices ranging from $30.25 to $30.88.
This transaction was effected under a Rule 10b5-1 trading plan, and she now directly holds 54,645 shares of Agios common stock.
AGIO insider Sarah Gheuens filed a notice to sell up to 30,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with a proposed sale date of 08/04/2026. The shares relate to prior equity awards, including 14,169 restricted stock units granted on 12/02/2020 and 15,831 performance shares granted on 04/14/2020. The filing also reports a recent sale of 4,007 shares for $150,517.75 on 07/01/2026.
Farallon Capital Management, L.L.C. and affiliated investment funds and individuals report beneficial ownership of 5,917,400 Shares of Agios Pharmaceuticals, Inc. common stock on an amended Schedule 13G. This represents 9.9% of the outstanding Shares as of the reporting date.
The Shares are held directly by a group of investment partnerships collectively referred to as the Farallon Funds, for which Farallon Capital Management, L.L.C. serves as investment manager. Farallon and a group of managing and senior managing members share voting and dispositive power over these Shares, while the Farallon Funds have the right to receive dividends and sale proceeds.
Agios Pharmaceuticals reported much higher rare-disease drug revenue for the quarter ended June 30, 2026, mainly from AQVESME and PYRUKYND, while remaining loss-making. Net product revenue reached $44,745 for the quarter and $65,491 for the first half of 2026, compared with $12,455 and $21,181 a year earlier, with most growth from U.S. sales and rising rest-of-world contributions.
The company recorded a quarterly net loss of $100,703 and a six‑month net loss of $199,814, reflecting continued investment in R&D and commercialization. Operating expenses were $155,297 for the quarter, including $25,000 of in‑process R&D from a new global license for cevidoplenib from Oscotec. Cash, cash equivalents and marketable securities totaled $1.0 billion as of June 30, 2026, which management expects will fund current operations for at least twelve months.
Mitapivat remains the core asset, marketed as AQVESME in U.S. thalassemia and PYRUKYND in PK deficiency and other regions. A supplemental New Drug Application for sickle cell disease is under FDA priority review with a PDUFA goal date of November 1, 2026, supported by the ongoing REIGNITE phase 3 trial. Additional programs, including AG‑181 for phenylketonuria and AG‑236 for polycythemia vera, advanced through early clinical stages, while the Oscotec deal added cevidoplenib for immune thrombocytopenia and other autoimmune indications.
Agios Pharmaceuticals reported second-quarter 2026 results highlighted by sharp growth in mitapivat revenue. Worldwide net revenues from PYRUKYND and AQVESME were $44.7 million, up from $12.5 million a year earlier. Net loss was $100.7 million, compared to $112.0 million, or $1.69 per share.
U.S. mitapivat revenue reached $40.9 million and ex-U.S. revenue $3.8 million, with 442 cumulative AQVESME prescriptions for thalassemia written by REMS‑certified U.S. physicians. PYRUKYND received European Commission marketing authorization for thalassemia, and mitapivat is now approved for adults with thalassemia in the U.S., Saudi Arabia, United Arab Emirates, and EU.
The FDA accepted Agios’ sNDA for mitapivat in sickle cell disease with Priority Review and a November 1, 2026 PDUFA goal date, and the first patient was dosed in the REIGNITE Phase 3 trial. Agios licensed cevidoplenib for immune thrombocytopenia, advanced AG‑236 toward Phase 2/3 in polycythemia vera and AG‑181 in PKU, discontinued tebapivat programs, and ended the quarter with $964.8 million in cash, cash equivalents and marketable securities.